Funding for this research was provided by:
Norwegian Health Association (na)
Fullbright Scholar Program
Text and Data Mining valid from 2018-11-19
Received: 25 January 2018
Accepted: 31 October 2018
First Online: 19 November 2018
Ethics approval and consent to participate
: The study was approved by the Regional Committees for Medical and Health Research Ethics (REC South East, ref. number 2015/2122). As part of the approval exemption from consent to participate was waived based on The Health Research Act §35, §9 and §33; (i) notification of LTBI treatment in Norway is mandatory without asking for consent, (ii) treatment initiation not affected by the study, (iii) screening for TB is mandatory, which makes the monitoring and evaluation of the yield and safety of screening essential.
: Not applicable.
: The authors declare that they have no competing interests.
: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.